Sökning: (L773:1352 4585 OR L773:1477 0970) srt2:(2020-2024) >
CLADCOMS - CLADribi...
-
Fink, K.Academic Specialist Center, Centrum for Neurology, Stockholm, Sweden; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
(författare)
CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
Sage Publications,2022
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-102594
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-102594URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:vet swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Cladribine is a deoxyadenosine analogue prodrug that selectively induces immune reconstitution by targeting B- and T-lymphocytes. Cladribine tablets (CladT) are administered in two courses, 12 months apart, for patients with relapsing multiple sclerosis (RMS). Post-marketing surveillance is important for evaluation of long-term safety and effectiveness in a real-world setting. CLADCOMS (CLADribine tablets long-term Control Of MS) is a post-marketing investigator driven study. Here we report one year follow-up data on the first 100 patients included in the study in April 2021.Objective: 1) To investigate for how long a full dose treatment with Cladribine 10 mg tablets (3.5 mg/kg over two years) offers freedom of disease activity in relapsing MS patients.2) To collect complete data on safety and effectiveness with the help of the Swedish Neuroregistry to enable future assessment on effectiveness and safety in comparison with other in Sweden commonly used disease modifying treatments.Methods: CLADCOMS includes patients with relapsing MS from the eight academic clinics starting Cladribine treatment after 23rd of March 2018. Data is collected in the Swedish Neuroregistry using highly structured yearly follow-up routines. Descriptive data on relapses, MRI activity, Patient Reported Outcome Measures and Serious Adverse events (SAEs) from the first 100 patient included in the study are obtained from the registry.Results: Up to April 2022 1XX patients were included in the study. In April 2021 the first 100 patient entered the study. 40% of patients included were treatment naïve, 29% switched from natalizumab and 13% from rituximab. By April 2022, 5 patients experienced a relapse during the treatment initiation and showed MRT activity with contrast enhancing (CEL)lesions more than six months after initiation of treatment, of which 2 patients showed CEL more than six months after the second treatment course year two. 20% of the patients showed new lesions on the first MRI performed up to 18 months after treatment initiation. Two patients reported SEAs. Analysis of CD19 and CD27- B-cells counts over time will be performed.Conclusions: Cladribine treatment demonstrates clinical stability in patients treated ⩾ 12 months. However, continued follow-up is needed to assess the effectiveness and safety of treatment with Cladribine over a longer time to investigate time to disease reactivation after the second treatment course year two has been administered.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nilsson, P.Lund University, Department of Neurology, Lund, Sweden
(författare)
-
Alonso, L.Lund University, Department of Neurology, Lund, Sweden
(författare)
-
Sveningsson, A.Danderyd Hospital, Department of Clinical Science, Stockholm, Sweden
(författare)
-
Gunnarsson, Martin,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology(Swepub:oru)mign
(författare)
-
Lange, Niclas,1990-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurology(Swepub:oru)nle
(författare)
-
Ayad, A.Capio S:t Göran Hospital, Neurologiska kliniken, Stockholm, Sweden
(författare)
-
Vrethem, M.Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden
(författare)
-
Burman, J.Uppsala University, Department of Neuroscience, Uppsala, Sweden
(författare)
-
Lycke, J.University of Gothenburg, Department of Clinical Neuroscience, Gothenburg, Sweden
(författare)
-
Piehl, F.Academic Specialist Center, Centrum for Neurology, Stockholm, Sweden; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
(författare)
-
Academic Specialist Center, Centrum for Neurology, Stockholm, Sweden; Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, SwedenLund University, Department of Neurology, Lund, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Multiple Sclerosis Journal: Sage Publications28:Suppl. 3, s. 847-8481352-45851477-0970
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Fink, K.
-
Nilsson, P.
-
Alonso, L.
-
Sveningsson, A.
-
Gunnarsson, Mart ...
-
Lange, Niclas, 1 ...
-
visa fler...
-
Ayad, A.
-
Vrethem, M.
-
Burman, J.
-
Lycke, J.
-
Piehl, F.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Multiple Scleros ...
- Av lärosätet
-
Örebro universitet